Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

Mette Gyldenløve,Howraman Meteran,Jennifer A. Sørensen,Simon Fage,Yiqiu Yao,Jesper Lindhardsen,Christoffer V. Nissen,Tanja Todberg,Simon F. Thomsen,Lone Skov,Claus Zachariae,Lars Iversen,Mia-Louise Nielsen,Alexander Egeberg

The Lancet Regional Health - Europe（2023）

Cited 1|Views24

No score

Abstract

Financial support was received from Herlev and Gentofte Hospital, University of Copenhagen, and independent grants from private foundations in Denmark. No pharmaceutical company, including the market authorization holder of roflumilast, was involved in the study at any point.

Translated text

Key words

Psoriasis, Roflumilast, PDE4-inhibitor, Phosphodiesterase-4, Therapy, Chronic obstructive pulmonary disease, COPD

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined